Insys Therapeutic's Pharmaceutical Cannaabidiol(CBD) gets US FDA Orphan Drug status for treatment of GLIOBLASTOMA MULTIFORME(GBM) .In addition Insys entered in to an exclusive license agreement with CPMCRI,California Pacific medical center research institute to license patent rights related to usage of CANNABINOIDS for treatment of GLIOBLASTOMA MULTIFORME(GBM).
GBM,glioblastoma multiforme is a most common form of primary brain tumours and also most aggressive forms of Cancer. Treating glioblastoma is very difficult due to a variety of complicated factors like tumours cells are very resistant to conventional therapies,bran is susceptible to damage with conventional therapy,most of the drugs do not cross BLOOD -BRAIN barrier. etc
Insys is in process of evaluating potenial use of pharmaceutical Cannabinoids in other treatments like in chemotherapy induced peripheral neuropathy,epilepsy,addiction in cocaine,opioids and amphetmaines.
GBM,glioblastoma multiforme is a most common form of primary brain tumours and also most aggressive forms of Cancer. Treating glioblastoma is very difficult due to a variety of complicated factors like tumours cells are very resistant to conventional therapies,bran is susceptible to damage with conventional therapy,most of the drugs do not cross BLOOD -BRAIN barrier. etc
Insys is in process of evaluating potenial use of pharmaceutical Cannabinoids in other treatments like in chemotherapy induced peripheral neuropathy,epilepsy,addiction in cocaine,opioids and amphetmaines.
Latest update :Insys therapeutics will present at the Morgan Stanley Global Healthcare Conference 2014 to be held fro September 8 to 10 at Grand Hyatt ,New York. Michael L. Babich ,president and CEO ,Darryl Baker (CFO) will host the presentation.